Viatris (VTRS) Cash & Equivalents Growth (1y) (2020 - 2026)
Viatris (VTRS) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | 69.13% |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 2.86% |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | 19.56% |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 13.19% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 56.51% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 25.91% |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | -1.67% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | -4.65% |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn | -1.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.51% |
| Mar 31, 2026 | 138.97% |
| Dec 31, 2025 | 79.65% |
| Sep 30, 2025 | -48.09% |
| Jun 30, 2025 | -38.25% |
| Mar 31, 2025 | -25.59% |
| Dec 31, 2024 | -25.79% |
| Sep 30, 2024 | 43.46% |
| Jun 30, 2024 | 45.77% |
| Mar 31, 2024 | 100.28% |
| Dec 31, 2023 | -21.43% |
| Sep 30, 2023 | 102.51% |
| Jun 30, 2023 | -5.34% |
| Mar 31, 2023 | -32.67% |
| Dec 31, 2022 | 78.77% |
| Sep 30, 2022 | -14.53% |
| Jun 30, 2022 | -1.37% |
| Mar 31, 2022 | -6.75% |
| Dec 31, 2021 | -16.92% |
| Mar 31, 2021 | 40.97% |